New-onset diabetes after liver transplantation and its impact on complications and patient survival

Journal of Diabetes

Volumn 7, Issue 6, 2015, Pages 881-890

  Lv, Chaoyang ^a   Zhang, Yao ^a   Chen, Xianying ^a,c   Huang, Xiaowu ^a   Xue, Mengjuan ^a   Sun, Qiman ^a   Wang, Ting ^a   Liang, Jing ^a   He, Shunmei ^a   Gao, Jian ^b   Zhou, Jian ^a   Yu, Mingxiang ^a   Fan, Jia ^a   Gao, Xin ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c Department of Radiology Hainan Provincial Nongken Hospital   (China)

Author keywords

Fasting plasma glucose; Liver transplantation; New onset diabetes after transplant; Postoperative complications

Indexed keywords

GLUCOSE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 DERIVATIVE; INTERLEUKIN 2 RECEPTOR; RAPAMYCIN; TACROLIMUS; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; INCIDENCE; KIDNEY FAILURE; LIVER TRANSPLANTATION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; MULTIPLE ORGAN FAILURE; NEW ONSET DIABETES AFTER TRANSPLANTATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SEPSIS; TUMOR RECURRENCE; ADVERSE EFFECTS; BLOOD; CHI SQUARE DISTRIBUTION; CHINA; COMPLICATION; DIET RESTRICTION; DONOR; EPIDEMIOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROTECTION; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ADULT; BIOMARKERS; BLOOD GLUCOSE; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; CHINA; DIABETES MELLITUS; FASTING; FATTY LIVER; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROTECTIVE FACTORS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84944676425     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12275     Document Type: Article

References (68)

1. Merion RM. Current status and future of liver transplantation. Semin Liver Dis. 2010; 30: 411-421.
2. Bruns H, Hillebrand N, Schneider T etal. Lab MELD-based organ allocation increases total costs of liver transplantation: A single-center experience. Clin Transplant. 2011; 25: E558-565.
3. China Liver Transplant Registry. Annual scientific report of Chinese liver transplant in 2012. 2013. Available from: http://www.cltr.org/pages/statistics/statistics_livercount (accessed 2 June 2013).
4. Bruns H, Lozanovski VJ, Schultze D etal. Prediction of postoperative mortality in liver transplantation in the era of MELD-based liver allocation: A multivariate analysis. PLoS ONE. 2014; 9: e98782.
5. Davidson JA, Wilkinson A. New-onset diabetes after transplantation 2003 international consensus guidelines: An endocrinologist's view. Diabetes Care. 2004; 27: 805-812.
6. Wilkinson A, Davidson J, Dotta F etal. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005; 19: 291-298.
7. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: Diagnosis and classification of diabetes mellitus: Provisional report of a WHO consultation. Diabet Med. 1998; 15: 539-553.
8. Jenssen T, Hartmann A. Prevention and management of transplant-associated diabetes. Expert Opin Pharmacother. 2011; 13: 2641-2655.
9. Hecking M, Kainz A, Werzowa J etal. Glucose metabolism after renal transplantation. Diabetes Care. 2013; 36: 2763-2771.
10. Valderhaug TG, Hjelmesaeth J, Jenssen T, Roislien J, Leivestad T, Hartmann A. Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses. Transplantation. 2012; 94: 714-720.
11. Hecking M, Haidinger M, Doller D etal. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012; 23: 739-749.
12. Werzowa J, Hecking M, Haidinger M etal. Vidagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: A randomized, placebo-controlled clinical trial. Transplantation. 2013; 95: 456-462.
13. Parekh J, Corley DA, Feng S. Diabetes, hypertension and hyperlipidemia: Prevalence over time and impact on long-term survival after liver transplantation. Am J Transplant. 2012; 12: 2181-2187.
14. John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl. 2002; 8: 708-713.
15. Moon JI, Barbeito R, Faradji RN, Gaynor JJ, Tzakis AG. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: Long-term follow up. Transplantation. 2006; 82: 1625-1628.
16. Rakel A, Karelis AD. New-onset diabetes after transplantation: Risk factors and clinical impact. Diabetes Metab. 2011; 37: 1-14.
17. Hanouneh IA, Feldstein AE, McCullough AJ etal. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl. 2008; 14: 1287-1293.
18. Foxton MR, Quaglia A, Muiesan P etal. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2006; 6: 1922-1929.
19. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012; 35 (Suppl. 1): S64-71.
20. Tiniakos DG. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: Histological diagnostic criteria and scoring systems. Eur J Gastroenterol Hepatol. 2010; 22: 643-650.
21. Valderhaug TG, Hjelmesæth J, Hartmann A etal. The association of early post-transplant glucose levels with long-term mortality. Diabetologia. 2011; 54: 1341-1349.
22. Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol. 2008; 3: 814-821.
23. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003; 3: 178-185.
24. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000; 11: 1735-1743.
25. Honda M, Asonuma K, Hayashida S etal. Incidence and risk factors for new-onset diabetes in living-donor liver transplant recipients. Clin Transplant. 2013; 27: 426-435.
26. Carey EJ, Aqel BA, Byrne TJ etal. Pretransplant fasting glucose predicts new-onset diabetes after liver transplantation. J Transplant. 2012; doi:10.1155/2012/614781.
27. Hjelmesaeth J, Asberg A, Muller F, Hartmann A, Jenssen T. New-onset posttransplantation diabetes mellitus: Insulin resistance or insulinopenia? Impact of immunosuppressive drugs, cytomegalovirus and hepatitis C virus infection. Curr Diabetes Rev. 2005; 1: 1-10.
28. Valderhaug TG, Jenssen T, Hartmann A etal. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation. 2009; 88: 429-434.
29. Hecking M, Werzowa J, Haidinger M etal. Novel views on new-onset diabetes after transplantation: Development, prevention and treatment. Nephrol Dial Transplant. 2013; 28: 550-566.
30. Lida S, Ishida H, Tokumoto T etal. New-onset diabetes after transplantation in tarcrolimus-treated, living kidney transplantation: Long-term impact and utility of the pre-transplant OGTT. Int Urol Nephrol. 2010; 42: 935-945.
31. Moon JI, Barbeito R, Faradji RN etal. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: Long-term follow up. Transplantation. 2006; 82: 1625-1628.
32. Saliba F, Lakehal M, Pageaux GP etal. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: An observational multicenter study. Liver Transpl. 2007; 13: 136-144.
33. Veroux M, Corona D, Giuffrida G etal. New-onset diabetes mellitus after kidney transplantation: The role of immunosuppression. Transplant Proc. 2008; 40: 1885-1887.
34. Lv C, Chen M, Xu M etal. Influencing factors of new-onset diabetes after a renal transplant and their effects on complications and survival rate. PLoS ONE. 2014; 9: e99406.
35. Santos L, Rodrigo E, Pinera C etal. New-onset diabetes after transplantation: Drug-related risk factors. Transplant Proc. 2012; 44: 2585-2587.
36. Yang J, Hutchinson II, Shah T, Min DI. Genetic and clinical risk factors of new-onset diabetes after transplantation in Hispanic kidney transplant recipients. Transplantation. 2011; 91: 1114-1119.
37. Lane JT, Dagogo-Jack S. Approach to the patient with new-onset diabetes after transplant (NODAT). J Clin Endocrinol Metab. 2011; 96: 3289-3297.
38. Matas AJ, Gillingham KJ, Humar A etal. Posttransplant diabetes mellitus and acute rejection: Impact on kidney transplant outcome. Transplantation. 2008; 85: 338-343.
39. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008; 19: 1411-1418.
40. Saab S, Shpaner A, Zhao Y etal. Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation. Am J Transplant. 2006; 6: 1890-1895.
41. Anastacio LR, Ribeiro HS, Ferreira LG, Lima AS, Vilela EG, Toulson Davisson Correia MI. Incidence and risk factors for diabetes, hypertension and obesity after liver transplantation. Nutr Hosp. 2013; 28: 643-648.
42. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation. 2010; 89: 1-14.
43. Pascual J, Galeano C, Royuela A, Zamora J. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation. 2010; 90: 343-349.
44. Vitko S, Klinger M, Salmela K etal. Two corticosteroid-free regimes - tacrolimus monotherapy after basiliximab administration and tarcrolimus/mycophenolate mofetil - in comparison with a standard triple regimen in renal transplantation: Results of the Atlas study. Transplantion. 2005; 80: 1734-1741.
45. Gotthardt DN, Bruns H, Weiss KH, Schemmer P. Current strategies for immunosuppression following liver transplantation. Langenbecks Arch Surg. 2014; 399: 981-988.
46. Sgourakis G, Radtke A, Fouzas I etal. Corticosteroid-free immunosuppression in liver transplantation: A meta-analysis and meta-regression of outcomes. Transpl Int. 2009; 22: 892-905.
47. Segev DL, Sozio SM, Shin EJ etal. Steroid avoidance in liver transplantation: Meta-analysis and meta-regression of randomized trials. Liver Transpl. 2008; 14: 512-525.
48. Beckebaum S, Cicinnati VR, Radtke A, Kabar I. Calcineurin inhibitors in liver transplantation-still champions or threatened by serious competitors? Liver Int. 2013; 33: 656-665.
49. Konrad T, Steinmuller T, Vicini P etal. Regulation of glucose tolerance in patients after liver transplantation: Impact of cyclosporin versus tacrolimus therapy. Transplantation. 2000; 69: 2072-2078.
50. Hahn HJ, Laube F, Lucke S, Kloting I, Kohnert KD, Warzock R. Toxic effects of cyclosporine on the endocrine pancreas of Wistar rats. Transplantation. 1986; 41: 44-47.
51. Hornum M, Jørgensen KA, Hansen JM etal. New-onset diabetes mellitus after kidney transplantation in Denmark. Clin Am J Soc Nephrol. 2010; 5: 709-716.
52. Midtvedt K, Jenssen T, Hartmann A etal. No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus. Nephrol Dial Transplant. 2011; 26: 3767-3772.
53. Correia MITD, Rego LO, Lima AS. Post-liver transplant obesity and diabetes. Curr Opin Clin Nutr Metab Care. 2003; 6: 457-460.
54. Roque J, Rios G, Hepp J etal. Sirolimus for rescue of recurrent acute rejection and diabetes mellitus after liver transplantation: Report of one case. Rev Med Chil. 2005; 133: 1221-1224.
55. Goralczyk AD, Hauke N, Bari N, Tsui TY, Lorf T, Obed A. Interleukin 2 receptor antagonists for liver transplant recipients: A systematic review and meta analysis of controlled studies. Transpl Int. 2011; 24: 86-87.
56. Kato T, Gaynor JJ, Yoshida H etal. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: Impact on hepatic fibrosis progression at one year. Transplantation. 2007; 84: 829-835.
57. ter Meulen CG, van Riemsdijk I, Hene RJ etal. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: A prospective, randomized, multicenter study. Am J Transplant. 2004; 4: 803-810.
58. Xu X, Ling Q, He ZL, Gao F, Zheng SS. Post-transplant diabetes mellitus in liver transplantation: Hangzhou experience. Hepatobiliary Pancreat Dis Int. 2008; 7: 465-470.
59. Wallia A, Parikh ND, Molitch ME, Gao F, Zheng SS. Posttransplanthyperglycemia is associated with increased risk of liver allograft rejection. Transplantation. 2010; 89: 222-226.
60. Sunder-Plassmann G, Fodinger M, Saemann DM. Cardiovascular diseases mortality in kidney transplant recipient: No light at the end of the tunnel? Am J Kidney Dis. 2012; 59: 754-757.
61. Sharif A, de Vries AP, Porrini E, Hecking M, Saemann MD, European-New-Onset Diabetes After Transplantation Working Group. Clinical trials for treatment of NODAT: Time to collaborate. Transplantation. 2012; 94: e23-24.
62. Neetha S, Biju T, Amita R. Comparison of neutrophil function in diabetic and healthy subjects with chronic generalized periodontitis. J Indian Soc Periodontol. 2008; 12: 41-44.
63. John PR, Thuluvath PJ. Outcome of liver transplantation in patients with diabetes mellitus: A case-control study. Hepatology. 2001; 34: 889-5.
64. Aldosary AA, Ramji AS, Elliott TG etal. Post-liver transplantation diabetes mellitus: An association with hepatitis C. Liver Transpl. 2002; 8: 356-361.
65. Chen HF, Chen P, Li CY. Risk of malignant neoplasm of the pancreas in relation to diabetes: A population-based study in Taiwan. Diabetes Care. 2011; 34: 1177-1179.
66. Rabkin JM, Melena V, Orloff SL, Corless CL, Rosen HR, Olyaei AJ. Late mortality after orthotopic liver transplantation. Am J Surg. 2001; 181: 475-479.
67. Lukes DJ, Herlenius G, Rizell M etal. Late mortality in 679 consecutive liver transplant recipients: The Gothenburg liver transplant experience. Transplant Proc. 2006; 38: 2671-2672.
68. Gelson W, Hoare M, Dawwas MF, Vowler S, Gibbs P, Alexander G. The pattern of late mortality in liver transplant recipients in the United Kingdom. Transplantation. 2011; 91: 1240-1244.